Skip to main content
letter
. 2021 Aug 10;35(9):2727–2730. doi: 10.1038/s41375-021-01380-5

Fig. 1. Antibody levels following BNT162b mRNA Covid19 vaccine after a median of 22 and 100 days after the second dose in patients with CLL.

Fig. 1

a Time course following BNT162b mRNA Covid19 vaccine, each dot represents immune response level for the whole cohort. b Time course following BNT162b mRNA Covid19 vaccine, each dot represents immune response level only for patients with CLL who were tested positive in the first serology test. c Arrow diagram presenting the dynamics of antibody value along 100 days of follow-up.